CoChat
Sign Up
Cited by 53Thyroid Cancer Diagnosis and TreatmentThyroid Disorders and TreatmentsRadiopharmaceutical Chemistry and Applications

The importance of sodium/iodide symporter (NIS) for thyroid cancer management

Open access
Carvalho, Denise P., Ferreira, Andrea C.F.·2007·Arquivos Brasileiros de Endocrinologia & Metabologia
DOI 10.1590/s0004-27302007000500004
Open this paper in CoChat — free accountOpen PDF

Abstract

The thyroid gland has the ability to uptake and concentrate iodide, which is a fundamental step in thyroid hormone biosynthesis. Radioiodine has been used as a diagnostic and therapeutic tool for several years. However, the studies related to the mechanisms of iodide transport were only possible after the cloning of the gene that encodes the sodium/iodide symporter (NIS). The studies about the regulation of NIS expression and the possibility of gene therapy with the aim of transferring NIS gene to cells that normally do not express the symporter have also become possible. In the majority of hypofunctioning thyroid nodules, both benign and malignant, NIS gene expression is maintained, but NIS protein is retained in the intracellular compartment. The expression of NIS in non-thyroid tumoral cells in vivo has been possible through the transfer of NIS gene under the control of tissue-specific promoters. Apart from its therapeutic use, NIS has also been used for the localization of metastases by scintigraphy or PET-scan with 124I. In conclusion, NIS gene cloning led to an important development in the field of thyroid pathophysiology, and has also been fundamental to extend the use of radioiodine for the management of non-thyroid tumors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/s0004-27302007000500004

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Iodide uptake is a fundamental step in thyroid hormone biosynthesis, and TPO is a key enzyme in thyroid hormone biosynthesis.

    “Iodide uptake is a fundamental step in thyroid hormone biosynthesis, and TPO is a key enzyme in thyroid hormone biosynthesis (Dai et al. 1996, Carvalho & Ferreira 2007); therefore, the decreased thyroid hormone levels appear to be secondary to the decreased NIS function and TPO activity.”

    From Administration of 3,5-diiodothyronine (3,5-T2) causes central hypothyroidism and stimulates thyroid-sensitive tissues (2014) · cites this paper as Carvalho & Ferreira 2007

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 95

  1. Baumann E. Uber den Jodgehalt der Schilddrüsen Von Menchen und Tieren. Hoppe Seylers Z Physiol Chem 1896;22:1-17.
  2. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 1948;174:555-64.
  3. Cardoso LC, Martins DC, Campos DV, Santos LM, Correa da Costa VM, Rosenthal D, et al. Effect of iodine or iopanoic acid on thyroid Ca 2+ /NADPH-dependent H 2 O 2 -generating activity and thyroperoxidase in toxic diffuse goiters. Eur J Endocrinol 2002;147(3):293-8.
  4. Heufelder AE, Morgenthaler N, Schipper ML, Joba W. Sodi- um iodide symporter-based strategies for diagnosis and treatment of thyroidal and nonthyroidal malignancies. Thy- roid 2001;11:839-47.
  5. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:485-60.
  6. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996;226:339-45.
  7. Eskandari S, Loo DDF, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na + /I -Symporter -mechanism, stoichiometry, and specificity. J Biol Chem 1997;272:27230-8.
  8. Scott DA, Wang R, Kreman TM, Sheffield VC, Karniski LP. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet 1999;21(4):440-3.
  9. van den Hove MF, Croizet-Berger K, Jouret F, Guggino SE, Gug- gino WB, Devuyst O, et al. The loss of the chloride channel, ClC- 5, delays apical iodide efflux and induces a euthyroid goiter in the mouse thyroid gland. Endocrinology 2006;147:1287-96.
  10. Taurog A. Hormone synthesis: Thyroid iodine metabolism. In: Braverman LE, Utiger RD (eds). The Thyroid: A Funda- mental and Clinical Text. 8 th ed. Philadelphia: Lippincott Williams & Wilkins, 2000. pp. 61-85.
  11. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regu- lation, and medical significance. Endocr Rev 2003;24:48-77.
  12. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Rapid communication: predominant intracellular overexpression of the Na + /I -symporter (NIS) in a large sampling of thyroid can- cer cases. J Clin Endocrinol Metab 2001;86:2697-700.
  13. Dohan O, Carrasco N. Advances in Na + /I -symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 2003;213(1):59-70.
  14. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001;276:21458-63.
  15. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implica- tions. Eur J Endocrinol 2006;155(4):495-512.
  16. Spitzweg C, Morris JC. Approaches to gene therapy with sodi- um/iodide symporter. Exp Clin Endocrinol 2001;109:56-9.
  17. Reizer J, Reizer A, Saier MH Jr. A functional superfamily of sodium/solute symporters. Biochim Biophys Acta 1994;1197(2):133-66.
  18. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997;138(8):3555-8.
  19. Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, et al. Characterization of the thyroid Na + /I -symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci USA 1997;94:5568-73.
  20. Levy O, De la Vieja A, Ginter CS, Riedel C, Dai G, Carrasco N. N-linked glycosylation of the thyroid Na + /I -symporter (NIS). Implications for its secondary structure model. J Biol Chem 1998;273:22657-63.
  21. Fujiwara H, Tatsumi K, Miki K, Harada T, Okada S, Nose O, et al. Recurrent T354P mutation of the Na + /I -symporter in patients with iodide transport defect. J Clin Endocrinol Metab 1998;83(8):2940-3.
  22. Dohan O, Gavrielides MV, Ginter C, Amzel LM, Carrasco N. Na + /I -symporter activity requires a small and uncharged amino acid residue at position 395. Mol Endocrinol 2002;16(8):1893-902.
  23. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. Na + /I - symport activity is present in membrane vesicles from thy- rotropin-deprived non-I -transporting cultured thyroid cells. Proc Natl Acad Sci USA 1994;91:3789-93.
  24. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP- dependent transcription. Mol Cell Biol 1999;19(3):2051-60.
  25. Tonacchera M, Viacava P, Agretti P, de Marco G, Perri A, di Cosmo C, et al. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. J Clin Endocrinol Metab 2002;87:352-7.
  26. Ferreira AC, Lima LP, Araújo RL, Muller G, Rocha RP, Rosen- thal D, et al. Rapid regulation of thyroid sodium-iodide sym- porter activity by thyrotrophin and iodine. J Endocrinol 2005;184(1):69-76.
  27. Braverman LE, Ingbar SH. Changes in thyroidal function dur- ing adaptation to large doses of iodide. J Clin Invest 1963;42:1216-31.
  28. Eng PHK, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, et al. Escape from the acute Wolff-Chaikoff effect is associat- ed with a decrease in thyroid sodium/iodide symporter mes- senger ribonucleic acid and protein. Endocrinology 1999;140:3404-10.
  29. Grollman EF, Smolar A, Ommaya A, Tombaccini D, Santiste- ban P. Iodine suppression of iodide uptake in FRTL-5 thyroid cells. Endocrinology 1986;118:2477-82.
  30. Pisarev MA. Thyroid autoregulation. J Endocrinol Invest 1985;8(5):475-84.
  31. Pereira A, Braekman JC, Dumont JE, Boeynaems JM. Identi- fication of a major iodolipid from the horse thyroid gland as 2-iodohexadecanal. J Biol Chem 1990;265(28):17018-25.
  32. Fukuda H, Greer M, Roberts L, Allen CE, Critcholow V, Wilson M. Nyctohemeral and sex-related variations in plasma thy- rotropin, thyroxinne, and triiodotironine. Endocrinology 1975;97:1424-30.
  33. Urban RJ. Neuroendocrinology of aging in the male and female. Endocrinol Metab Clin North Am 1992;21:921-31.
  34. Furlanetto TW, Nguyen LQ, Jameson JL. Estrogen increases proliferation and down-regulates the sodium/iodide sym- porter gene in FRTL-5. Endocrinology 1999;140:5705-11.
  35. Chen HJ, Walfish PG. Effects of age and ovarian function on the pituitary-thyroid system in female rats. J Endocrinol 1978;78:225-32.
  36. Christianson D, Roti E, Vagenakis AG, Braverman LE. The sex-related difference in serum thyrotropin concentration is androgen mediated. Endocrinology 1981;108:529-35.
  37. Fisher JS, D'Angelo SA. Stimulatory and inhibitory action of estrogen on TSH secretion. Endocrinology 1971;88:687-91.
  38. Lisboa PC, Curty FH, Moreira RM, Pazos-Moura CC. Effects of estradiol benzoate on 5'-iodotironine deiodinase activities in female rat anterior pituitary gland, liver and thyroid gland. Braz J Med Biol Res 1997;30:1479-84.
  39. Boccabella AV, Alger EA. Influence of estradiol on thyroid: serum radioiodine concentration ratios of gonadectomized and hypophysectomized rats. Endocrinology 1964;74:680-8.
  40. Hiasa Y, Kitahori Y, Yane K, Nishioka H, Nakahashi K, Konishi N, et al. Establishment of estrogen receptor-positive trans- plantable rat thyroid tumor cell lines in vivo. Cancer Res 1993;53:4408-12.
  41. Banu SK, Govindarajulu P, Aruldhas MM. Testosterone and estradiol up-regulate androgen and estrogen receptors in immature and adult rat thyroid glands in vivo. Steroids 2002;67:1007-14.
  42. Lima LP, Barros IA, Lisboa PC, Araújo RL, Silva AC, Rosenthal D, et al. Estrogen effects on thyroid iodide uptake and thy- roperoxidase activity in normal and ovariectomized rats. Steroids 2006;71(8):653-9.
  43. Marcus M, Coulton AM. Fat-soluble vitamins A, K, E. In: Had- man JG, Limbird LE, Gilman AG (eds). Goodman and Gilmamn's The Pharmacologic Basis of Therapeutics. Mc Graw Hill, 2000. pp. 1773-92.
  44. Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab. 2000;85:2889-96.
  45. Schmutzler C, Winzer R, Maissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of function symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.
  46. Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.
  47. Van Herle AJ, Agatep ML, Padua DN, Totanes TL, Canlapan DV, Van Herle HML, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-63.
  48. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: thera- peutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-74.
  49. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fim- mers R, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998;39:1903-6.
  50. Schmutzler C, Köhrle J. Retinoic acid redifferentiation thera- py for thyroid cancer. Thyroid 2000;10:393-405.
  51. Simon D, Körber C, Krausch M, Segering J, Groth P, Görges R, et al. Clinical impact of retinoids in redifferentiation thera- py of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med 2002;29:775-82.
  52. Grüning T, Tiepolts C, Zöphel K, Bradow J, Kropp J, Franke W- G. Retinoic acid for redifferentiation of thyroid cancer -does it hold its promise? Eur J Endocrinol 2003;148:395-402.
  53. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thy- roid carcinoma. J Endocrinol Invest 2004;27(4):334-9.
  54. Coelho SM, Vaisman M, Carvalho DP. Tumour re-differentia- tion effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 2005;11(19):2525-31.
  55. Monzani F, Caraccio N, Casolaro A, Lombardo F, Moscato G, Murri L, et al. Long-term interferon β-1b therapy for MS: is routine thyroid assessment always useful? Neurology 2000;22:549-52.
  56. Rotondi M, Mazziotti G, Biondi B, Manganella G, Del Buono AD, Montella P, et al. Long-term treatment with interferon- beta therapy for multiple sclerosis and occurrence of Graves' disease. J Endocrinol Invest 2000;23(5):321-4.
  57. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, et al. Thyroid function and autoimmunity during interferon β-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86(8):3525-32.
  58. Caraccio N, Giannini R, Cuccato S, Faviana P, Berti P, Galleri D, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005;90(2):1156-62.
  59. Ajjan RA, Watson PF, Findlay C, Metcalfe RA, Crisp M, Ludgate M, et al. The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. J Endocrinol 1998;158(3):351-8.
  60. Spitzweg C, Joba W, Morris JC, Heufelder AE. Regulation of sodium iodide symporter gene expression in FRTL-5 rat thy- roid cells. Thyroid 1999;9(8):821-30.
  61. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;25;389(6649):349-52.
  62. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20(8):615-26.
  63. Katan-Khaykovich Y, Struhl K. Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of nor- mal histone acetylation status upon removal of activators and repressors. Genes Dev 2002;16(6):743-52.
  64. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na + /I -symporter and iodine accumulation in poorly dif- ferentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86(7):3430-5.
  65. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Tri- chostatin A, a histone deacetylase inhibitor. Surgery 2002;132(6):984-90.
  66. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide sym- porter thyroperoxidase and thyroglobulin. Endocrinology 2004;145(6):2865-75.
  67. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G. Valproic acid induces the expression of the Na + /I -symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004;89(2):1006-9.
  68. Kitazono M, Chuman Y, Aikou T, Fojo T. Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86(2):834-40.
  69. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, et al. Effects of histone acetylation on sodium iodide sym- porter promoter and expression of thyroid-specific transcrip- tion factors. Endocrinology 2005;146(9):3967-74.
  70. Schmitt TL, Espinoza CR, Loos U. Transcriptional regulation of the human sodium/iodide symporter gene by Pax8 and TTF-1. Exp Clin Endocrinol Diabetes 2001;109(1):27-31.
  71. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thy- roid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differential- ly regulated in normal and thyroid cancer cells. Mol Endocrinol 2002;16(10):2266-82.
  72. Puppin C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, et al. Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. Mol Cell Endocrinol 2004;214(1-2):117-25.
  73. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription fac- tors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994;17:4744-9.
  74. Pasca di Magliano M, Di Lauro R, Tannini M. PAX8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 2000;221:13144-9.
  75. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, et al. Recovery of NIS expression in thyroid cancer cells by over- expression of Pax8 gene. BMC Cancer 2005;5(1):80.
  76. Suzuki K, Lavaroni S, Mori A, Ohta M, Saito J, Pietrarelli M, et al. Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci USA 1998;95(14):8251- 6.
  77. Dohan O, De la Vieja A, Carrasco N. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells. Mol Endocrinol 2006;20(5):1121-37.
  78. De la Vieja A, Ginter CS, Carrasco N. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na + /I -symporter. Mol Endocrinol 2005;19(11):2847-58.
  79. Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, et al. Evidence for tran- scriptional and posttranscriptional alterations of the sodi- um/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 2004;165(1):25-34.
  80. Mian C, Lacroix L, Alzieu L, Nocera M, Talbot M, Bidart JM, et al. Sodium iodide symporter and pendrin expression in human thyroid tissues. Thyroid 2001;11(9):825-30.
  81. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid can- cer. Am J Med 1994;97(5):418-28.
  82. Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, et al. Development of reverse transcription-com- petitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thy- roid 1999;9(4):405-9.
  83. Jhiang SM, Cho JY, Ryu KY, DeYoung BR, Smanik PA, McGaughy VR, et al. An immunohistochemical study of Na + /I -symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998;139(10):4416-9.
  84. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 1998;83(7):2493- 6.
  85. Dohan O, Carrasco N. Thyroidal iodide transport and thyroid cancer. Cancer Treat Res 2004;122:221-36.
  86. Cho JY. A transporter gene (sodium iodide symporter) for dual purposes in gene therapy: imaging and therapy. Curr Gene Ther 2002;2(4):393-402.
  87. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentra- tor gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59(3):661-8.
  88. Cho JY, Xing S, Liu X, Buckwalter TL, Hwa L, Sferra TJ, et al. Expression and activity of human Na + /I -symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000;7(9):740-9.
  89. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, et al. Treatment with drugs able to reduce iodine efflux signifi- cantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 2006;91(6):2389-95.
  90. Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate- specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res 2003;63(22):7840-4.
  91. Spitzweg C, Morris JC. Gene therapy for thyroid cancer: cur- rent status and future prospects. Thyroid 2004;14(6):424-34.
  92. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY, et al. In vivo sodium iodide symporter gene ther- apy of prostate cancer. Gene Ther 2001;8(20):1524-31.
  93. Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodi- um iodide symporter gene expression. J Clin Endocrinol Metab 2005;90(8):4457-64.
  94. Dingli D, Kemp BJ, O'Connor MK, Morris JC, Russell SJ, Lowe VJ. Combined 124 I positron emission tomography/com- puted tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol 2006;8(1):16-23.
  95. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribu- tion of perrhenate, pertechnetate, and iodide by Na/I sym- porter-expressing tissues in vivo. J Nucl Med 2004;45(3):500-7. 100.Dadachova E, Nguyen A, Lin EY, Gnatovskiy L, Lu P, Pollard JW. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol 2005;32(7):695-700. 101.Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium- 188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002;29(1):13-8. 102.Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Estab- lishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002;29(7):842-54.

Cited by

Sorted by citations

Authors
Carvalho, D. P., & Ferreira, A. C. F.
Affiliations
Universidade Federal do Rio de Janeiro (BR)
ORCID
Venue
Arquivos Brasileiros de Endocrinologia & Metabologia
Publisher
FapUNIFESP (SciELO)
Published
2007-07
Volume
51
Issue
5
Pages
672-682
ISSN
0004-2730 (ISSN-L)
DOI
10.1590/s0004-27302007000500004
OpenAlex
W2125096478
Cited by
53
References
0
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 6 · 2014: 4 · 2013: 5 · 2012: 4
FWCI
0.29
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Arquivos Brasileiros de Endocrinologia & Metabologia (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, cc-by-nc)
Funders
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
sodium iodide symporter, thyroid cancer, radioiodine therapy, iodide transport, NIS gene expression, metastasis localization, thyroid nodules
MeSH terms
Sodium-Iodide Symporters, Biological Transport, Carcinoma, Papillary, Cloning, Molecular, Humans, Iodides, Iodine, Iodine Radioisotopes, Thyroid Neoplasms, Thyrotropin, Genetic Therapy, Down-Regulation, Gene Expression, Gene Transfer Techniques, Adenocarcinoma, Follicular, Symporters

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review